文献速递流行病学与生物统计临床试验与 GCP

筛查幽门螺杆菌以预防胃癌:一项实用性随机临床试验

Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

该实用性随机临床试验在台湾彰化县50至69岁居民中比较邀请幽门螺杆菌粪便抗原检测联合粪便免疫化学检测与单独粪便免疫化学检测对胃癌发病率和死亡率的影响,共随机240000人。结果显示两组胃癌发病率和死亡率均无显著差异,但在校正筛查参与率和随访时间后,联合筛查组胃癌发病率较低,而胃癌死亡率无差异。

要点

  • 邀请幽门螺杆菌粪便抗原检测联合粪便免疫化学检测未显著降低胃癌发病率或死亡率。
  • 校正筛查参与率和随访时间后,联合筛查组胃癌发病率较低,但胃癌死亡率无差异。
  • 幽门螺杆菌粪便抗原阳性者中71.4%接受抗生素治疗,根除率达91.9%。

核心结论

  • 在台湾居民中,与单独邀请粪便免疫化学检测相比,邀请幽门螺杆菌粪便抗原检测联合粪便免疫化学检测未降低胃癌发病率或胃癌死亡率。
  • 在校正筛查参与率和随访时间差异后,联合筛查组胃癌发病率较低,但胃癌死亡率无差异。

研究设计与样本

  • 实用性随机临床试验,纳入台湾彰化县50至69岁符合每两年一次粪便免疫化学检测结肠癌筛查资格的居民。
  • 共随机240000名成人(平均年龄58.1岁,标准差5.6;46.8%女性),其中63508人被邀请接受幽门螺杆菌粪便抗原检测联合粪便免疫化学检测,88995人被邀请单独接受粪便免疫化学检测。
  • 研究于2014年1月1日至2018年9月27日进行,最终随访于2020年12月31日完成。
  • 240000名随机化者中,38792人无法联系,48705人未收到邀请,被排除。

主要发现

  • 邀请组中,幽门螺杆菌粪便抗原检测联合粪便免疫化学检测组的筛查参与率为49.6%(31497/63508),单独粪便免疫化学检测组为35.7%(31777/88995)。
  • 12142名幽门螺杆菌粪便抗原阳性参与者(38.5%)中,8664人(71.4%)接受抗生素治疗,根除率为91.9%。
  • 胃癌发病率在联合筛查组为0.032%,在单独粪便免疫化学检测组为0.037%(平均差-0.005%[95%CI,-0.013%至0.003%];P=0.23)。
  • 胃癌死亡率在联合筛查组为0.015%,在单独粪便免疫化学检测组为0.013%(平均差0.002%[95%CI,-0.004%至0.007%];P=0.57)。
  • 事后分析校正筛查参与率、随访时间和患者特征差异后,与单独粪便免疫化学检测相比,邀请幽门螺杆菌粪便抗原检测联合粪便免疫化学检测与较低的胃癌发病率相关(0.79[95%CI,0.63-0.98]),但与胃癌死亡率无关(1.02[95%CI,0.73-1.40])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effects of screening for Helicobacter pylori on gastric cancer incidence and mortality are unknown. OBJECTIVE: To evaluate the effects of an invitation to screen for H pylori on gastric cancer incidence and mortality. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic randomized clinical trial of residents aged 50 to 69 years in Changhua County, Taiwan, eligible for biennial fecal immunochemical tests (FIT) for colon cancer screening. Participants were randomized to either an invitation for H pylori stool antigen (HPSA) + FIT assessment or FIT alone. The study was conducted between January 1, 2014, and September 27, 2018. Final follow-up occurred December 31, 2020. INTERVENTION: Invitation for testing for H pylori stool antigen. MAIN OUTCOMES AND MEASURES: The primary outcomes were gastric cancer incidence and gastric cancer mortality. All invited individuals were analyzed according to the groups to which they were randomized. RESULTS: Of 240 000 randomized adults (mean age, 58.1 years [SD, 5.6]; 46.8% female), 63 508 were invited for HPSA + FIT, and 88 995 were invited for FIT alone. Of the 240 000 randomized, 38 792 who were unreachable and 48 705 who did not receive an invitation were excluded. Of those invited, screening participation rates were 49.6% (31 497/63 508) for HPSA + FIT and 35.7% (31 777/88 995) for FIT alone. Among 12 142 participants (38.5%) with positive HPSA results, 8664 (71.4%) received antibiotic treatment, and eradication occurred in 91.9%. Gastric cancer incidence rates were 0.032% in the HPSA + FIT group and 0.037% in the FIT-alone group (mean difference, -0.005% [95% CI, -0.013% to 0.003%]; P = .23). Gastric cancer mortality rates were 0.015% in the HPSA + FIT group and 0.013% in the FIT-alone group (mean difference, 0.002% [95% CI, -0.004% to 0.007%]; P = .57). After adjusting for differences in screening participation, length of follow-up, and patient characteristics in post hoc analyses, an invitation for HPSA + FIT was associated with lower rates of gastric cancer (0.79 [95% CI, 0.63-0.98]) but not with gastric cancer mortality (1.02 [95% CI, 0.73-1.40]), compared with FIT alone. Among participants who received antibiotics, the most common adverse effects were abdominal pain or diarrhea (2.1%) and dyspepsia or poor appetite (0.8%). CONCLUSIONS AND RELEVANCE: Among residents of Taiwan, an invitation to test for HPSA combined with FIT did not reduce rates of gastric cancer or gastric cancer mortality, compared with an invitation for FIT alone. However, when differences in screening participation and length of follow-up were accounted for, gastric cancer incidence, but not gastric cancer mortality, was lower in the HSPA + FIT group, compared with FIT alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01741363.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lee YC, Chiang TH, Chiu HM, et al. Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial. JAMA. 2024. PMID: 39348147. doi:10.1001/jama.2024.14887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。